Ananda Pharma (STU:1FX) Total Stockholders Equity: €0.34 Mil (As of Jul. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Ananda Pharma Total Stockholders Equity?

Ananda Pharma STU:1FX Total Stockholders Equity is €0.34 Mil as of Jul. 2025. The stock has 5 warning signs investors should review.

Ananda Pharma's Total Stockholders Equity for the quarter that ended in Jul. 2025 was €0.34 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Ananda Pharma's Book Value per Share for the quarter that ended in Jul. 2025 was €0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Ananda Pharma's Debt-to-Equity for the quarter that ended in Jul. 2025 was 2.69.

Ananda Pharma  (STU:1FX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Ananda Pharma's Book Value per Share for the quarter that ended in Jul. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(0.34152731907737-0)/4299.146581
=0.00

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Ananda Pharma's Debt-to-Equity for the quarter that ended in Jul. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.91766757939802 + 0) / 0.34152731907737
=2.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ananda Pharma Total Stockholders Equity Related Terms

Ananda Pharma Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Ananda Pharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ananda Pharma Total Stockholders Equity Chart

Ananda Pharma Annual Data
Trend Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25
Total Stockholders Equity
Get a 7-Day Free Trial 0.94 0.34 1.37 0.41 2.54

Ananda Pharma Semi-Annual Data
Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23 Jan24 Jul24 Jan25 Jul25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.65 0.41 -1.02 2.54 0.34
What does a Total Stockholders Equity of €0.34 Mil mean?
Ananda Pharma (STU:1FX) has a Total Stockholders Equity of €0.34 Mil as of Jul. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Ananda Pharma and its competitors.
Is Ananda Pharma's Total Stockholders Equity too high?
Ananda Pharma's current Total Stockholders Equity is €0.34 Mil.
How does Ananda Pharma's Total Stockholders Equity compare to ZTS and UTHR?
Ananda Pharma's Total Stockholders Equity of €0.34 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Ananda Pharma and its competitors. Ananda Pharma's current Total Stockholders Equity is €0.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ananda Pharma stock overvalued right now?
Ananda Pharma (STU:1FX) has a current Total Stockholders Equity of €0.34 Mil. The current Total Stockholders Equity is €0.34 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Ananda Pharma (STU:1FX), the current Total Stockholders Equity is €0.34 Mil as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ananda Pharma Business Description

Address 60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Ananda Pharma PLC is a UK-based biopharmaceutical company developing regulatory-approved, cannabidiol medicines to treat complex, chronic conditions, including endometriosis (funded by NHS Scotland) and chemotherapy-induced peripheral neuropathy (funded by NIHR).